Fiche centre
University of California, Los Angeles
Los Angeles — United States
Essais liés14clinical trials
VilleLos Angeleslocalisation
PaysUnited Stateslocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04626674
Essais cliniques associés
14| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Radical Prostatectomy | Cancer | Non applicable | NCT05027477 | CAPTAIN — A Comparison of TULSA Procedure vs. Radical Prostatectomy in Participants With Localized Prostate Cancer | ACTIVE_NOT_RECRUITING |
| Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | Myopathies | À vérifier | NCT06503367 | Observation Study in Patients Age 0-5 Years With LAMA2-related Congenital Muscular Dystrophy | RECRUITING |
| NEU-411 | Parkinson | Phase 2 | NCT06680830 | NEULARK — A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | RECRUITING |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06132893 | RISE 2 — A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | RECRUITING |
| Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | Myopathies | À vérifier | NCT03981575 | Estab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | RECRUITING |
| ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1 | Myopathies | À vérifier | NCT05224778 | ASPIRE-DM1 — DMCRN-02-001: Assessing Pediatric Endpoints in DM1 | RECRUITING |
| Neuraceq | Alzheimer | À vérifier | NCT05617014 | ADNI4 — Alzheimer's Disease Neuroimaging Initiative 4 | ENROLLING_BY_INVITATION |
| delandistrogene moxeparvovec | Myopathies | Phase 1 | NCT04626674 | ENDEAVOR — A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort | RECRUITING |
| 5% lidocaine/5 mg/ml 0.02% estradiol compound cream | Migraine | Phase 2 | NCT03844412 | Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments | COMPLETED |
| TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | SEP | Non applicable | NCT03500328 | TREAT-MS — Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial | ACTIVE_NOT_RECRUITING |
| ASSESS ALL ALS Study | Sclérose latérale amyotrophique | À vérifier | NCT06578195 | ASSESS ALL ALS Study | RECRUITING |
| ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | Sclérose latérale amyotrophique | À vérifier | NCT04363684 | ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) | RECRUITING |
| Hydroxychloroquine | Lupus | Phase 3 | NCT05799378 | SHIELD — Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | RECRUITING |
| ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | Alzheimer | À vérifier | NCT01078636 | ADNI-GO — Alzheimer's Disease Neuroimaging Initiative Grand Opportunity | COMPLETED |